News

The alliance brings together and leverages etherna’s mRNA capabilities and LNP formulations with Almirall’s expertise in medical dermatology to speed up the discovery of new treatment options. The

The company entered into the asset purchase agreement in accordance with Regulation 596/2014/EU. Lavipharm is expected to commercialise the product on completing the relevant marketing authorisation transfer, set

AML is a fast-developing cancer originating in the blood and bone marrow, impacting myeloid cells that typically transform into different types of mature blood cells. REZLIDHIA is a

With this acceptance, NextPoint Therapeutics now intends to begin a first-in-human Phase I clinical trial in early 2024 analysing NPX887 in patients with solid tumours known to express

ALS is a progressive neurodegenerative disease which sees motor neurons atrophy and die, leading to loss of the ability to speak, move, eat and, ultimately even breathe. Voyager

People suffering with PNH condition have an acquired mutation that makes their red blood cells susceptible to destruction in a premature way by the complement system. A Factor

The new, first-in-class inhibitor is being assessed to treat a range of immune-mediated disorders, including lupus nephritis (LN), the most common secondary immune-mediated glomerular disease. Following the acceptance,

ELAHERE is a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC). The deal will see ImmunoGen’s follow-on pipeline of next-generation ADCs complement the ADC platform and

The partnership has been formed through Astella’s wholly-owned subsidiary Xyphos Biosciences. They will assess the potential of antibodies, developed by Phenomic and designed for a novel tumour stroma